US Inhalation Systems Market Forecast up to 2024

  • Product Code:
    RP-ID-10078151
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    98
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
US Inhalation Systems Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview:
The emergence of inhaled drug therapy has been a boon for patients with respiratory conditions such as COPD and asthma because of its painless and flexible administration when compared to injections. There are various kinds of inhalation systems available in the market, and these include inhalers and nebulizers. The two most commonly widespread respiratory diseases are asthma and COPD. According to WHO, around 235 million people are currently suffering from asthma, and it is very common in children. Chronic respiratory diseases such as asthma and COPD are responsible for substantial financial and health burden in the US, and in 2015, 6.7% deaths in the US were due to chronic respiratory diseases. Chronic obstructive pulmonary disease is the third leading cause of death across the globe, accounting for approximately 3 million deaths in 2016. State of West Virginia has the highest prevalence of COPD, and around 12% of the population are diagnosed with COPD.
The US inhalation systems market is driven by an upsurge in the prevalence of respiratory diseases, increasing geriatric population, and favorable reimbursement. However, side effects allied with the drug inhalation and unattainability of single effective inhaler device that can treat many disease conditions may slow down the growth of the market in the US.
Market Analysis: The “US Inhalation Systems Market” is estimated to witness a CAGR of 5.8% during the forecast period 2018–2024. The US market is analyzed based on three segments – products, applications, and end-users.
Product Analysis: The US inhalation systems market, by product, is segmented into inhalers and nebulizers. The market by inhalers type is further segmented into dry powder inhalers and metered dose inhalers. The market by nebulizers is segmented into ultrasonic nebulizer, pneumatic nebulizer, and mesh nebulizer. Inhalers occupied a major market share in 2017 and nebulizers segment is anticipated to grow at a high CAGR during the forecast period. The extensive usage of inhalers in the treatment of various respiratory illness such as asthma, chronic obstructive pulmonary disorder, and others makes the segment the major shareholder.
Application Analysis: The US inhalation systems market, by application, is segmented into asthma, chronic obstructive pulmonary disease (COPD), and others. Asthma occupied a major market share in 2017 and COPD is expected to grow at the highest rate in the next five years.
End-users Analysis: The US inhalation systems market by end-users is segmented into hospitals, ambulatory care centers, and home care centers. Hospitals occupied a major market share in 2017, and home care segment is expected to grow during the forecast period due to ease in the usage of modern products, less homecare cost, and the obtainability of reimbursement.
Key Players:
Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson and Company are few of the key players in the US inhalation systems market.
Competitive Analysis:
There is an increase in approvals in recent years due to the popularity of the systems and also drug companies are launching new inhalation systems and collaborating with other vendors to develop innovative devices in the market. For instance, in February 2017, FDA approved two products developed by Teva Pharmaceutical Industries Ltd., ArmonAir RespiClick and AirDuo RespiClick, to treat adolescent and adult patients with asthma. In October 2017, FDA approved new inhalation device, named TD-300/A developed by United Therapeutics Corporation, for use with Tyvaso Inhalation Solution. The first triple combination inhaler named Trimbow launched for COPD in August 2017 and in February 2018, Teva Pharmaceutical Industries Ltd. announced the commercial availability of QVAR RediHaler Inhalation Aerosol to patients in the US.
Benefits: The report provides complete details about the products offered by inhalation system companies in various therapeutic verticals. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Contents
1 Industry Outlook 8
1.1 Industry Overview 8
1.2 Industry Trends 9
2 Report Outline 10
2.1 Report Scope 10
2.2 Report Summary 10
2.3 Research Methodology 11
2.4 Report Assumptions 12
3 Market Snapshot 13
3.1 Market Definition – Infoholic Research 13
3.2 Advantages of Inhalation Systems 13
3.3 Limitations Associated with Inhalation Systems 13
3.4 Segmented Addressable Market 13
3.5 Trends in the US Inhalation Systems Market 14
3.6 Related Markets 15
3.6.1 Sleep Apnea Devices 15
3.6.2 Anesthesia Devices 15
3.6.3 Pulmonary Medicine 16
4 Market Outlook 17
4.1 History of Inhalation Systems 17
4.2 Market Segmentation 17
4.3 PEST Analysis 18
4.4 Porter 5(Five) Forces 19
5 Market Characteristics 21
5.1 DRO Analysis – Market Dynamics 21
5.1.1 Drivers 21
5.1.1.1 Rising prevalence of respiratory diseases 21
5.1.1.2 Favorable reimbursement 22
5.1.1.3 Increasing geriatric population 22
5.1.2 Opportunities 22
5.1.2.1 Advancements in technology 22
5.1.2.2 Upsurge in demand for home-care therapeutic devices 23
5.1.3 Restraints 23
5.1.3.1 Side effects allied with drug inhalation 23
5.1.3.2 Unattainability of solo effective inhaler device that can treat many disease conditions 23
5.2 DRO – Impact Analysis 24
5.3 Key Stakeholders 25
6 Products: Market Size and Analysis 26
6.1 Overview 26
6.2 Inhalers 27
6.2.1 Dry Powder Inhalers 29
6.2.2 Metered Dose Inhalers 30
6.2.3 Soft Mist Inhalers 31
6.3 Nebulizers 32
6.3.1 Ultrasonic Nebulizers 33
6.3.2 Pneumatic/Jet Nebulizers 34
6.3.3 Mesh Nebulizers 35
7 Applications: Market Size and Analysis 37
7.1 Overview 37
7.2 Asthma 37
7.3 Chronic Obstructive Pulmonary Disease (COPD) 38
7.4 Others 38
8 End-users: Market Size and Analysis 40
8.1 Overview 40
8.2 Hospitals 40
8.3 Ambulatory Care Centers 41
8.4 Home Care 41
9 Americas: Market Size and Analysis 42
9.1 Overview 42
9.2 US 42
10 Competitive Landscape 44
10.1 Overview 44
11 Vendors Profile 46
11.1 Boehringer Ingelheim GmbH 46
11.1.1 Overview 46
11.1.2 Business Units 48
11.1.3 Geographic Presence 49
11.1.4 Business Focus 50
11.1.5 SWOT Analysis 50
11.1.6 Business Strategies 51
11.2 Omron Corp. 51
11.2.1 Overview 51
11.2.2 Business Units 53
11.2.3 Geographic Presence 54
11.2.4 Business Focus 55
11.2.5 SWOT Analysis 55
11.2.6 Business Strategies 56
11.3 PARI GmbH 56
11.3.1 Overview 56
11.3.2 Business Focus 57
11.3.3 SWOT Analysis 57
11.3.4 Business Strategies 58
11.4 Philips Healthcare 58
11.4.1 Overview 58
11.4.2 Business Units 67
11.4.3 Geographic Presence 68
11.4.4 Business Focus 69
11.4.5 SWOT Analysis 70
11.4.6 Business Strategies 70
11.5 3M 71
11.5.1 Overview 71
11.5.2 Business Units 73
11.5.3 Geographic Presence 74
11.5.4 Business Focus 74
11.5.5 SWOT Analysis 74
11.5.6 Business Strategies 75
12 Companies to Watch For 76
12.1 AptarGroup, Inc. 76
12.1.1 Overview 76
12.2 Teleflex Incorporated 77
12.2.1 Overview 77
12.3 Agilent Technologies 78
12.3.1 Overview 78
12.4 Inspiro Medical Ltd. (A Subsidiary of OPKO Health, Inc.) 82
12.4.1 Overview 82
12.5 Monaghan Medical Corporation 83
12.5.1 Overview 83
12.6 AstraZeneca PLC 84
12.6.1 Overview 84
12.7 GlaxoSmithKline plc 85
12.7.1 Overview 85
12.8 Teva Pharmaceuticals Industries Ltd. 88
12.8.1 Overview 88
12.9 Beckton Dickinson and Company 90
12.9.1 Overview 90
Annexure 92
Abbreviations 92


Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Omron Corp., Boehringer Ingelheim GmbH, PARI GmbH, Philips Healthcare, Teleflex Incorporated, 3M, AptarGroup, Inc., Agilent Technologies, Inc., AstraZeneca PLC, Inspiro Medical Ltd., Teva Pharmaceutical Industries Ltd., Monaghan Medical Corporation, GlaxoSmithKline plc, Becton Dickinson
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports